Floatz logo

Recombinant Fowlpox-CEA(6D)

Male Breast Cancer

National Cancer Institute (NCI)Phase 1Dormant
CC
44/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
29/ 100
Competitive Position
89/ 100

Competitive context

10 Active assets in the Male Breast Cancer cohort.

Asset / SponsorPhaseRating
Inno-206
National Cancer Institute (NCI)
Phase 2BBB
FILGRASTIM
University of Washington
Phase 2BBB
Cyclophosphamide
Wake Forest University Health Sciences
Phase 2BBB
Irinotecan
University of California, Irvine
Phase 2BBB
Cediranib
University of Chicago
Phase 2BB

View all 50 →

Same molecule, other indications

Recombinant Fowlpox-CEA(6D) is also rated in:

breast cancerDormant
CC
Indicative ·
47 / 100
View asset →
metastatic neoplasmDormant
CC
Indicative ·
45 / 100
View asset →
Adult Solid NeoplasmDormant
CC
Indicative ·
44 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →